MDACC Study No:2008-0425 ( NCT No: NCT00770731)
Title:A Phase I Study of Temsirolimus, Topotecan, and Bortezomib in Patients with Advanced Malignancy
Principal Investigator:Daniel Karp
Treatment Agent:Bortezomib; Temsirolimus; Topotecan
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of Torisel (temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade
(bortezomib) that can be given, in combination, to patients with advanced
cancer that has spread or is unable to be surgically removed. The safety of
this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:Bortezomib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patients will return to clinic on Days 1, 4, 8, 11, 15 and 21 of each cycle.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Daniel Karp
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-794-1226
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults